Phase 2 N=166 BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Cancer
Primary: Number of Participants With Adverse Events — 3; 4; 36; 50 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=274 A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
BRAF V600E Mutation Positive · Metastatic Colorectal Cancer
Primary: Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients — 17; 6; 10; 1 Participants
Phase 2 N=95 Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
BRAF V600E-mutant Metastatic Colorectal Cancer
Primary: Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments — 47.8 percentage of confirmed responses
Phase 2 N=106 S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression-free Survival — 2.0; 4.3 months — p=0.001
Phase 2 N=107 A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
BRAF V600E · Metastatic Colorectal Cancer
Primary: Safety Lead-in Phase (SLI): Incidence of Dose Limiting Toxicities (DLTs) — 0 Participants
Phase 3 N=702 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
BRAF V600E-mutant Metastatic Colorectal Cancer
Primary: (Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs) — 5 Participants
Phase 2 N=156 Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Phase 1b: Number of Participants With Incidence of Dose Limiting Toxicities (DLTs): Cycle 1 — 0; 1; 1; 1 Participants
Phase 2 N=208 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
Multiple Myeloma, Neoplasms
Primary: Confirmed Best Overall Response Rate (BORR) — 37.1; 50.0; 0; 7.4 percentage of participants
Phase 2 N=154 Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rate — 56.47; 37.93 percentage of participants
Phase 2 N=94 A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Percentage of Participants With Objective Response — 3; 20 Percentage of Participants — p=0.0735
Phase 2 N=36 Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
Colorectal Cancer · Neoplasm Metastasis
Primary: Response Rate for the Combination Treatment — 21 Participants
Phase 2 N=72 Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Phase 3 N=811 Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
Colorectal Cancer
Primary: OS in Participants With Left-sided Tumors — 37.85; 34.30 Months
Phase 2 N=21 Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
MSS · RAS-mutant Colorectal Cancer
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) — 1; 2 Participants
Phase 1 N=82 MEK and MET Inhibition in Colorectal Cancer
Solid Tumor · Colorectal Cancer
Primary: Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066 — 0; 0; 0; 1 Dose Limiting Toxicities (DLTs)
Phase 2 N=102 Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Metastatic Colorectal Carcinoma · Stage IV Colorectal Cancer AJCC v8 · Stage IVA Colorectal Cancer AJCC v8
Primary: Progression Free Survival (PFS) — 2.3; 2.2 months
Phase 2 N=51 BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Overall Rate of Response — 15 percentage of participants
Phase 2 N=68 Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
Metastatic Colorectal Cancer · KRAS Gene Mutation
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 1; 3 Participants
Phase 2 N=56 PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
Colon Cancer
Primary: Overall Response Rate — 32 percentage of participants
Phase 2 N=33 Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rates (RECIST 1.1) — 42.4 Percentage of participants
Phase 2 N=8 BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
BRAF Mutant Metastatic Melanoma
Primary: Phase 1 - Safety & Recommended Phase 2 Dose (RP2D) — 60 mg
Phase 2 N=177 Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Cancer
Primary: Overall Response Rate (ORR) — 27; 39; 23; 4 Participants
Phase 2 N=53 Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
Colorectal Cancer · Metastatic Cancer
Primary: Objective Response — 1; 3; 2 Participants
Phase 2 N=17 A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
Advanced BRAF Mutant Cancers
Primary: Dose-limiting Toxicities (DLTs) — 0 DLTs
Phase 2 N=70 Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
Colorectal Neoplasms
Primary: Overall Survival (OS) Time — 6.71 Months
Phase 2 N=32 Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
Advanced Colorectal Cancer
Primary: Progression-free Survival Rate at Three Months — 20.7 percentage of participants
Phase 1 N=54 A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Melanoma and Metastatic Colorectal Cancer
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) During Dose Escalation Phase — 0; 1; 0; 0 Participants
Phase 2 N=17 LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Change in Kinase Expression — -20.87259; -19.64376; -16.41738; -12.5401 Sum Log 2 Fold Change Kinase Expression
Phase 2 N=6 MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum
Primary: Progression Free Survival (PFS) — 0; 0 Participants
Phase 2 N=1 Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Ameloblastoma · BRAF Gene Mutation
Primary: Tumor Response — 0; 0; 0; 0 Participants